[Acute monocytic leukemia and acute myelomonocytic leukemia: treatment using VP 16213].
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005960:Glucosides / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D005960:Glucosides; D003561:Cytarabine; D011034:Podophyllotoxin
La leucémie aiguë monocytoïde et la lecémie aiguë myblomonocytïde: le traitement par le vp 16213